SCHEMBL1661841

SCHEMBL1661841

S=C=Nc1ccc(Cl)nc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.38
ALDH1A1 P00352 1/20 0.38
NR3C1 P04150 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADRA2A P08913 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
ADRA2C P18825 1/20 0.38
MAOA P21397 1/20 0.38
DRD1 P21728 1/20 0.38
SLC6A4 P31645 1/20 0.38
HTR2B P41595 1/20 0.38
CCR2 P41597 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
APLNR P35414 1/20 0.33
MIF P14174 1/20 0.32
CRHBP P24387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31230877 1.00 ABCB11 (0.38) ABCB11ALDH1A1NR3C1CYP1A2CYP3A4
SCHEMBL21597423 0.80 ALDH1A1 (0.36) ABCB11ALDH1A1NR3C1CYP1A2CYP3A4
SCHEMBL191977 0.80 ALDH1A1 (0.36) ABCB11ALDH1A1NR3C1CYP1A2CYP3A4
SCHEMBL1483874 0.79 CYP3A4 (0.38) ALDH1A1CYP3A4HPGDTDP1GABRA1
SCHEMBL10436334 0.72 ALDH1A1 (0.41) ABCB11ALDH1A1NR3C1CYP1A2CYP3A4
SCHEMBL10071721 0.71 CYP3A4 (0.32) CYP3A4CRHBPCRHR2
SCHEMBL1661864 0.71 CRHBP (0.39) ABCB11ALDH1A1NR3C1CYP1A2CYP3A4
SCHEMBL4782036 0.71 MAOA (0.51) ABCB11ALDH1A1NR3C1CYP1A2CYP3A4
SCHEMBL24553955 0.70 ALDH1A1 (0.30) ALDH1A1
SCHEMBL30167003 0.70 SIRT2 (0.34) ABCB11ALDH1A1NR3C1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023163033-A1 NOVEL COMPOUND, α-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF 国立研究開発法人量子科学技術研究開発機構 2023-08-31 WO disclosed
EP-2306994-B1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC (US) 2013-08-14 EP disclosed
EP-2306994-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF Amgen, Inc (US) 2011-04-13 EP disclosed
US-7842685-B2 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-11-30 US disclosed
US-20100029611-A1 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-02-04 US disclosed
WO-2009154775-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029611-A1 S1P1 receptor agonists and use thereof S1PR1, S1PR5, S1PR2 ABCB11 1734/4885ALDH1A1 1637/4885NR3C1 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.